Zanubrutinib
Brukinsa is a prescription medication containing the active ingredient zanubrutinib. It belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors and is used to treat certain types of blood cancers, including mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The medication works by targeting and blocking the BTK protein, which helps slow the progression of cancer cells.
Brukinsa is a BTK inhibitor used to treat certain blood cancers by blocking cancer cell growth and survival pathways.
Key facts at a glance
- RxNorm
- 2262441
- Generic
- Brukinsa
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Brukinsa is FDA-approved for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, Waldenström macroglobulinemia, marginal zone lymphoma (MZL) who require systemic therapy, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).
Brukinsa is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking the activity of BTK, a protein that plays a key role in the development and survival of B-cells. By inhibiting BTK, the medication disrupts signals that promote cancer cell proliferation and survival, helping to control the growth of cancer cells.
Common side effects may include diarrhea, bruising, and upper respiratory tract infections. Brukinsa may increase the risk of bleeding, infections, and heart rhythm problems. It may also cause other cancers, including skin cancer. Patients should inform their healthcare provider about all medications and supplements they are taking, as drug interactions may occur. Regular blood monitoring and follow-up appointments are important during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 3, 2026. · Read our editorial policy